CAS 83150-76-9

Acétate d'octréotide

Description :

Acétate d'octréotide est un octapeptide synthétique qui imite l'hormone naturelle somatostatine, jouant un rôle crucial dans la régulation de divers processus physiologiques, y compris la sécrétion hormonale et la fonction gastro-intestinale. Il est principalement utilisé dans le domaine médical pour traiter des conditions telles que l'acromégalie, certains types de tumeurs neuroendocrines et la diarrhée sévère associée au syndrome carcinoïde. La substance se caractérise par sa capacité à inhiber la libération de l'hormone de croissance et d'autres hormones, aidant ainsi à gérer les symptômes liés à la surproduction hormonale. Acétate d'octréotide est généralement administré par injection sous-cutanée ou intramusculaire et a une demi-vie plus longue par rapport à la somatostatine, permettant une posologie moins fréquente. Sa structure chimique comprend une configuration cyclique qui améliore sa stabilité et sa puissance. La forme acétate améliore la solubilité et la biodisponibilité, la rendant adaptée à un usage thérapeutique. Comme pour tout médicament, les effets secondaires potentiels peuvent inclure des troubles gastro-intestinaux, des réactions au site d'injection et des altérations du métabolisme du glucose, nécessitant une surveillance attentive pendant le traitement.

Formule : C₄₉H₆₆N₁₀O₁₀S₂(C₂H₄O₂)

InChI : InChI=1/C49H66N10O10S2.C2H4O2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;1-2(3)4/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1H3,(H,3,4)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+;/m1./s1

Synonymes :

• L-cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl) propyl)-cyclic (2->7)-disulfide, (R-(R*,R*))
• OctreotideAcetate
• 10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-(phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (1:2)
• (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
• (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
• 1: PN: EP1118336 SEQID: 1 claimed protein
• 11: PN: US20030229017 PAGE: 13 claimed protein
• 14: PN: DE10147056 PAGE: 40 claimed protein
• 17: PN: US6268342 SEQID: 18 claimed protein
• 25: PN: WO2007081792 SEQID: 40 claimed protein
• L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide
• Longastatin
• Octreotide

Octreotide

CAS : 83150-76-9

A slow-release form of octreotide. Pamoate is the bivalent anion of pamoic acid (embonic acid, 4,4·-methylene-bis-(3-hydroxy-2-naphthoic acid)). CAS-number (octreotide pamoate): 135467-16-2.

Formule : C₄₉H₆₆N₁₀O₁₀S₂

Degré de pureté : > 98%

Masse moléculaire : 1019.26

Ref: 01-4076740

[R-(R*,R*)]-D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2→7)-disulfide

CAS : 83150-76-9

Formule : C₄₉H₆₆N₁₀O₁₀S₂

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 1019.2393

Ref: IN-DA003A7L

Octreotide-Phenylalanine-d8 Ditrifluoroacetate

CAS : 83150-76-9

Formule : C₄₉H₅₈D₈N₁₀O₁₀S₂·2C₂HF₃O₂

Masse moléculaire : 1027.30 2*114.02

Ref: 4Z-PO-036001

Octreotide

CAS : 83150-76-9

Formule : C₄₉H₆₆N₁₀O₁₀S₂

Masse moléculaire : 1019.24

Ref: 7W-GP4986

Octreotide

CAS : 83150-76-9

Octreotide

Degré de pureté : ≥98%

Masse moléculaire : 1019.24g/mol

Ref: 54-BUP00965

Octreotide

CAS : 83150-76-9

Octreotide (SMS 201-995) is a potent inhibitor of growth hormone, glucagon, and insulin.

Formule : C₄₉H₆₆N₁₀O₁₀S₂

Degré de pureté : 99.3% - 99.64%

Couleur et forme : White Powder

Masse moléculaire : 1019.24

Ref: TM-T2584

Octreotide-phenylalanine-d8 di-Trifluoroacetic Acid Salt

Produit contrôlé

CAS : 83150-76-9

Applications Labelled octapeptide analog of Somatostatin. A gastric antisecretory agent. Used in treatment of acromegaly.
References Bauer, W., et al.: Life Sci., 31, 1133 (1982), Plewe, G., et al.: Lancet, 2, 782 (1984), Kraenzlin, M.E., et al.: Experientia, 41, 738 (1985), del Pozo, E., et al.: Acta Endocrinol., 111, 433 (1986),

Formule : C₅₃H₆₀D₈F₆N₁₀O₁₄S₂

Couleur et forme : Neat

Masse moléculaire : 1255.34

Ref: TR-O239952

13C6-Lys Octreotide Trifluoroacetate

Produit contrôlé

CAS : 83150-76-9

Formule : C₄₃₁₃C₆H₆₆N₁₀O₁₀S₂•xC₂HF₃O₂

Couleur et forme : White To Off-White

Masse moléculaire : 1025.2011402

Ref: TR-O239958

Octreotide

CAS : 83150-76-9

Octreotide is a drug that belongs to the macrocycle class of polymers. It is used in the treatment of cancer, as well as for diseases such as diabetes mellitus and acromegaly. Octreotide has been shown to inhibit p-glycoprotein (P-gp) and other drug transporters, which leads to an increase in oral bioavailability. In addition, octreotide also inhibits cellular proliferation by interfering with intracellular signalling pathways and protein synthesis. This drug has been shown to have a wide range of biochemical properties and is being investigated as an investigational agent for the treatment of various cancers.

Formule : C₄₉H₆₆N₁₀O₁₀S₂

Degré de pureté : Min. 95%

Masse moléculaire : 1,019.24 g/mol

Ref: 3D-OCT-3738-PI

Octreotide

CAS : 83150-76-9

Octreotide is a synthetic somatostatin analogue used for the treatment of acromegaly and neuroendocrine tumours. In clinical settings, Octreotide is used for the treatment of vasoactive intestinal peptide-secreting tumours, growth hormone producing tumours, and pituitary tumours. Octreotide also displays efficacy in the treatment of cluster headaches, acute haemorrhage from liver cirrhosis, malignant bowel obstruction, and idiopathic intracranial hypertension. Octreotide exerts its organ protective effects through several mechanisms, including its ability to decrease the levels of endotoxin and the proinflammatory cytokines TNF-alpha and IL-1β, and by inhibiting hepatocellular apoptosis. Octreotide also exerts a protective effect in hepatic ischemia-reperfusion (HIR) injury, which often occurs after complex liver surgeries such as major resection or transplantation.

Masse moléculaire : 1,018.4 g/mol

Ref: 3D-CRB1001491